MGP
VRTX icon

Metis Global Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Metis Global Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.21M Sell
11,667
-999
-8% -$466K 0.13% 131
2025
Q4 		$5.74M Sell
12,666
-758
-6% -$327K 0.14% 128
2025
Q3 		$5.26M Sell
13,424
-694
-5% -$290K 0.12% 141
2025
Q2 		$6.29M Sell
14,118
-1,581
-10% -$729K 0.16% 108
2025
Q1 		$7.61M Buy
15,699
+1,814
+13% +$845K 0.21% 84
2024
Q4 		$5.59M Buy
13,885
+430
+3% +$199K 0.17% 101
2024
Q3 		$6.26M Buy
13,455
+1,007
+8% +$484K 0.19% 86
2024
Q2 		$5.83M Sell
12,448
-63
-0.5% -$27.3K 0.2% 79
2024
Q1 		$5.23M Buy
12,511
+72
+0.6% +$30.4K 0.19% 87
2023
Q4 		$5.06M Sell
12,439
-475
-4% -$175K 0.2% 87
2023
Q3 		$4.49M Buy
12,914
+1,411
+12% +$493K 0.22% 94
2023
Q2 		$4.05M Sell
11,503
-12
-0.1% -$4.04K 0.22% 93
2023
Q1 		$3.63M Buy
11,515
+2,311
+25% +$693K 0.23% 92
2022
Q4 		$2.66M Buy
9,204
+3,078
+50% +$938K 0.24% 101
2022
Q3 		$1.77M Buy
6,126
+351
+6% +$101K 0.29% 77
2022
Q2 		$1.63M Buy
5,775
+1,757
+44% +$470K 0.26% 87
2022
Q1 		$1.05M Buy
4,018
+1,756
+78% +$417K 0.13% 151
2021
Q4 		$497K Buy
+2,262
New +$440K 0.14% 164

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Metis Global Partners's VRTX Position: Q1 2026 in Review

Metis Global Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 7.9% in Q1 2026, selling an estimated $466K and leaving 11,667 shares worth $5.21M. The position accounts for 0.13% of the portfolio, ranked #131.

Metis Global Partners first reported a position in VRTX in Q4 2021 and has held it in 18 quarters since. The position peaked at $7.61M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Metis Global Partners held 11,667 shares of Vertex Pharmaceuticals worth $5.21M as of Q1 2026.
  • Metis Global Partners sold 999 Vertex Pharmaceuticals shares in Q1 2026, an estimated $466K.
  • Vertex Pharmaceuticals made up 0.13% of Metis Global Partners's portfolio in Q1 2026, its #131 holding.
  • Metis Global Partners first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Metis Global Partners's Vertex Pharmaceuticals position peaked at $7.61M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Metis Global Partners's 13F filing for Q1 2026, filed 7 May 2026.